USA - NYSE:SSB - US8404411097 - Common Stock
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.44B | 1.72B | 1.74B | 1.64B | 1.39B | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | 2.09B | 1.42B | 1.45B | 1.34B | 1.03B | |||
| Non Interest Income | 352.54M | 302.26M | 286.91M | 309.20M | 354.30M | |||
| Loan Loss Provision | 119.52M | 15.97M | 114.08M | 81.90M | -165.30M | |||
| Net Interest Income after Provision | 1.97B | 1.40B | 1.34B | 1.25B | 1.20B | |||
| Non Interest Expense | -1.41B | -1.00B | -994.58M | -929.70M | -948.40M | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | null | null | null | null | null | |||
| Research and Development | null | null | null | null | null | |||
| Selling, General, and Administrative Expenses | null | null | null | null | null | |||
| Operating Income | null | null | null | null | null | |||
| Interest Income/Expense | null | null | null | null | null | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | 912.15M | 700.25M | 630.85M | 633.40M | 604.30M | |||
| Income Tax | 217.02M | 165.47M | 136.54M | 137.30M | 128.70M | |||
| Net Income | 695.12M | 534.78M | 494.31M | 496.00M | 475.50M | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 7.2856 | 6.9668 | 6.4632 | 6.6 | 6.71 | |||
| Non GAAP EPS | 8.959999999999999 | 7.2 | 6.85 | 7.08 | 7.57 | |||
| Statistics | ||||||||
| Profit Margin | 28.44% | 31.13% | 28.42% | 30.15% | 34.27% | |||
All data in USD